COCH Envoy Medical, Inc.

Nasdaq www.envoymedical.com


$ 1.64 $ 0.06 (3.87 %)    

Friday, 24-Jan-2025 20:10:36 EST
QQQ $ 529.31 $ -3.01 (-0.57 %)
DIA $ 443.82 $ -1.26 (-0.28 %)
SPY $ 607.41 $ -1.78 (-0.29 %)
TLT $ 87.22 $ 0.39 (0.45 %)
GLD $ 255.77 $ 1.58 (0.62 %)
$ 1.61
$ 1.64
-- x --
-- x --
$ 1.64 - $ 1.64
$ 1.08 - $ 11.46
22,976
na
31.58M
$ 0.36
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-14-2024 09-30-2024 10-Q
2 08-12-2024 06-30-2024 10-Q
3 05-15-2024 03-31-2024 10-Q
4 04-01-2024 12-31-2023 10-K
5 11-17-2023 09-30-2023 10-Q
6 08-14-2023 06-30-2023 10-Q
7 05-15-2023 03-31-2023 10-Q
8 04-03-2023 12-31-2022 10-K
9 11-14-2022 09-30-2022 10-Q
10 08-15-2022 06-30-2022 10-Q
11 05-16-2022 03-31-2022 10-Q
12 03-31-2022 12-31-2021 10-K
13 11-12-2021 09-30-2021 10-Q
14 08-18-2021 06-30-2021 10-Q
15 05-17-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ascendiant-capital-maintains-buy-on-envoy-medical-raises-price-target-to-9

Ascendiant Capital analyst Edward Woo maintains Envoy Medical (NASDAQ:COCH) with a Buy and raises the price target from $8.7...

 envoy-medical-q3-2024-gaap-eps-037-misses-027-estimate-sales-5600k-miss-8333k-estimate

Envoy Medical (NASDAQ:COCH) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.2...

 peer-reviewed-journal-discuses-envoy-medicals-fully-implanted-acclaim-cochlear-implant

Study in Otology & Neurotology outlines early experiences and potential benefits of breakthrough fully implanted cochlear i...

 envoy-medical-receives-european-patent-no-3858425-titled-implantable-modular-cochlear-implant-system-with-communication-system-and-network

Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a hearing health company focused on fully implanted he...

 envoy-medical-announces-that-the-american-medical-association-current-procedural-terminology-editorial-panel-has-approved-five-category-iii-cpt-codes-for-totally-implantable-active-middle-ear-implants-a-crucial-development-for-the-cos-already-fda-approved-esteem-product

The Esteem® device is the only totally implantable active middle ear implant with FDA Approval, allowing the Company to be the ...

 brookline-capital-initiates-coverage-on-envoy-medical-with-buy-rating-announces-price-target-of-9

Brookline Capital analyst Tyler Bussian initiates coverage on Envoy Medical (NASDAQ:COCH) with a Buy rating and announces Pr...

 envoy-medical-awarded-patent-no-12081061-for-recharge-system-used-with-implantable-battery

Growing Portfolio of Patents Further Advances the Company's Mission to Develop Fully Implanted Devices for Those Suffering ...

 ascendiant-capital-maintains-buy-on-envoy-medical-raises-price-target-to-875

Ascendiant Capital analyst Edward Woo maintains Envoy Medical (NASDAQ:COCH) with a Buy and raises the price target from $8.5...

 envoy-medical-secures-lending-facility-of-10m-of-which-the-company-drew-5m-on-the-facility-at-its-origination

Glen Taylor, Committed Investor and Believer in Envoy Medical's Mission to Help People with Significant Hearing Loss, Provi...

 envoy-medical-q2-eps-027-misses-025-estimate-sales-6800k-miss-8250k-estimate

Envoy Medical (NASDAQ:COCH) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.2...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION